
-
Eagle Pharmaceuticals OTC Markets EXMKT:EGRX Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Location: 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, United States | Website: https://www.eagleus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
81.78M
Cash
15.35M
Avg Qtr Burn
-2.33M
Short % of Float
3.77%
Insider Ownership
11.64%
Institutional Own.
50.11%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ryanodex (dantrolene sodium) injectable Details MH (Malignant Hyperthermia) | Approved Quarterly sales | |
Vasopressin Details Vasodilary shock | Approved Quarterly sales | |
Bendeka (Bendamustine hydrochloride) injection Details CLL (Chronic Lymphocytic Leukemia) | Approved Quarterly sales | |
Belrapzo (Bendamustine hydrochloride injection) Details CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma) | Approved Quarterly sales | |
Intravenous Amisulpride Details Nausea and vomiting | Phase 3 Update | |
Intravenous Amisulpride Details Nausea and vomiting | Phase 2/3 Data readout | |
Landiolol Details Supraventricular tachycardia | Failed Discontinued |